2026 ICD-10-CM Diagnosis Code C88.01Waldenstrom macroglobulinemia, in remission
ICD-10-CM Codes›C00–D49›C81-C96›C88
- Billable — Valid for Submission
- Chronic Condition
C88.01 is a billable ICD-10-CM diagnosis code for waldenstrom macroglobulinemia, in remission. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Leukemia in remission.
Code Identity
Code Classification
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Waldenstrom Macroglobulinemia
a lymphoproliferative disorder characterized by pleomorphic b-lymphocytes including plasma cells, with increased levels of monoclonal serum immunoglobulin m. there is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. clinical features include anemia; hemorrhages; and hyperviscosity.
Code History & ChangesHistory
Replacement C88.01 replaces the following previously assigned code(s):
- Z85.79 - Prsnl hx of malig neoplm of lymphoid, hematpoetc & rel tiss
Questions About C88.01Overview
Is C88.01 (Waldenstrom macroglobulinemia) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report waldenstrom macroglobulinemia, in remission on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C88.01 group to?
When waldenstrom macroglobulinemia, in remission is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
